BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CytoDyn readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies CytoDyn's drugs run\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06699836-1012@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Leronlimab: Phase 2 readout est. (NCT06699836)
DESCRIPTION:Leronlimab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: CL
 OVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor
  Enriched Regimen\nEstimated primary completion: January 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/leronlimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06699836
URL:https://assetmemo.bio/drug/leronlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
